JP2014532168A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014532168A5 JP2014532168A5 JP2014530734A JP2014530734A JP2014532168A5 JP 2014532168 A5 JP2014532168 A5 JP 2014532168A5 JP 2014530734 A JP2014530734 A JP 2014530734A JP 2014530734 A JP2014530734 A JP 2014530734A JP 2014532168 A5 JP2014532168 A5 JP 2014532168A5
- Authority
- JP
- Japan
- Prior art keywords
- biomarkers
- beta cell
- level
- acid
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000090 biomarker Substances 0.000 claims 35
- AFENDNXGAFYKQO-VKHMYHEASA-N (S)-2-hydroxybutyric acid Chemical compound CC[C@H](O)C(O)=O AFENDNXGAFYKQO-VKHMYHEASA-N 0.000 claims 20
- 238000000034 method Methods 0.000 claims 20
- -1 linoleoyl lysophosphatidylcholine Chemical compound 0.000 claims 16
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 claims 12
- 230000003915 cell function Effects 0.000 claims 12
- 230000004053 pancreatic β cell dysfunction Effects 0.000 claims 10
- 230000003820 β-cell dysfunction Effects 0.000 claims 8
- 239000012472 biological sample Substances 0.000 claims 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 6
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims 6
- KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 claims 6
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 claims 6
- 239000000523 sample Substances 0.000 claims 5
- 230000001225 therapeutic effect Effects 0.000 claims 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 3
- FPRKGXIOSIUDSE-SYACGTDESA-N (2z,4z,6z,8z)-docosa-2,4,6,8-tetraenoic acid Chemical compound CCCCCCCCCCCCC\C=C/C=C\C=C/C=C\C(O)=O FPRKGXIOSIUDSE-SYACGTDESA-N 0.000 claims 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 3
- MPCAJMNYNOGXPB-SLPGGIOYSA-N 1,5-anhydro-D-glucitol Chemical compound OC[C@H]1OC[C@H](O)[C@@H](O)[C@@H]1O MPCAJMNYNOGXPB-SLPGGIOYSA-N 0.000 claims 3
- YAMUFBLWGFFICM-PTGWMXDISA-N 1-O-oleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C YAMUFBLWGFFICM-PTGWMXDISA-N 0.000 claims 3
- ASWBNKHCZGQVJV-HSZRJFAPSA-O 1-O-palmitoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP(O)(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-HSZRJFAPSA-O 0.000 claims 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 3
- WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 claims 3
- QHKABHOOEWYVLI-UHFFFAOYSA-N 3-methyl-2-oxobutanoic acid Chemical compound CC(C)C(=O)C(O)=O QHKABHOOEWYVLI-UHFFFAOYSA-N 0.000 claims 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 3
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims 3
- 235000021292 Docosatetraenoic acid Nutrition 0.000 claims 3
- SITLTJHOQZFJGG-XPUUQOCRSA-N Glu-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O SITLTJHOQZFJGG-XPUUQOCRSA-N 0.000 claims 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 3
- 239000004471 Glycine Substances 0.000 claims 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 3
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims 3
- LZOSYCMHQXPBFU-UHFFFAOYSA-N O-decanoylcarnitine Chemical compound CCCCCCCCCC(=O)OC(CC([O-])=O)C[N+](C)(C)C LZOSYCMHQXPBFU-UHFFFAOYSA-N 0.000 claims 3
- CXTATJFJDMJMIY-UHFFFAOYSA-N O-octanoylcarnitine Chemical compound CCCCCCCC(=O)OC(CC([O-])=O)C[N+](C)(C)C CXTATJFJDMJMIY-UHFFFAOYSA-N 0.000 claims 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 3
- 239000005642 Oleic acid Substances 0.000 claims 3
- 235000021319 Palmitoleic acid Nutrition 0.000 claims 3
- WHBMMWSBFZVSSR-UHFFFAOYSA-N R3HBA Natural products CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 3
- 239000004473 Threonine Substances 0.000 claims 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 3
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 3
- 229960003121 arginine Drugs 0.000 claims 3
- 229960003237 betaine Drugs 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 claims 3
- 229960003624 creatine Drugs 0.000 claims 3
- 239000006046 creatine Substances 0.000 claims 3
- MYFMARDICOWMQP-YUMQZZPRSA-N gamma-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CC[C@H](N)C(O)=O MYFMARDICOWMQP-YUMQZZPRSA-N 0.000 claims 3
- 108010064169 gamma-glutamyl-leucine Proteins 0.000 claims 3
- 235000013922 glutamic acid Nutrition 0.000 claims 3
- 239000004220 glutamic acid Substances 0.000 claims 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 3
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims 3
- 229960004488 linolenic acid Drugs 0.000 claims 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 3
- GDTXICBNEOEPAZ-BQYQJAHWSA-N trans-10-heptadecenoic acid Chemical compound CCCCCC\C=C\CCCCCCCCC(O)=O GDTXICBNEOEPAZ-BQYQJAHWSA-N 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 2
- 230000001771 impaired effect Effects 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 229960000074 biopharmaceutical Drugs 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 238000001050 pharmacotherapy Methods 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 238000011477 surgical intervention Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161534679P | 2011-09-14 | 2011-09-14 | |
| US61/534,679 | 2011-09-14 | ||
| PCT/US2012/054640 WO2013039898A1 (en) | 2011-09-14 | 2012-09-11 | Biomarkers related to insulin resistance and methods using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014532168A JP2014532168A (ja) | 2014-12-04 |
| JP2014532168A5 true JP2014532168A5 (enExample) | 2015-10-08 |
| JP6158186B2 JP6158186B2 (ja) | 2017-07-05 |
Family
ID=47883643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014530734A Active JP6158186B2 (ja) | 2011-09-14 | 2012-09-11 | インスリン抵抗性に関連するバイオマーカーおよびそれを使用する方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10302663B2 (enExample) |
| EP (1) | EP2756095A4 (enExample) |
| JP (1) | JP6158186B2 (enExample) |
| WO (1) | WO2013039898A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3026266B1 (ja) | 1999-03-26 | 2000-03-27 | 光昭 佐々木 | 懸垂蒲鉾型鉗子式頸椎牽引具 |
| US20140324460A1 (en) * | 2012-09-26 | 2014-10-30 | Health Diagnostic Laboratory, Inc. | Method for determining and managing total cardiodiabetes risk |
| US10191032B2 (en) * | 2013-01-11 | 2019-01-29 | True Health Ip Llc | Method of detection and treatment of clinically significant post-prandial hyperglycemia in normoglycemic patients |
| JP6773951B2 (ja) * | 2014-05-30 | 2020-10-21 | 学校法人東京医科大学 | 唾液試料の調製方法 |
| WO2015200901A1 (en) | 2014-06-26 | 2015-12-30 | The Trustees Of Columbia University In The City Of New York | Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells |
| WO2016126923A1 (en) | 2015-02-06 | 2016-08-11 | Metabolon, Inc. | Diagnostic methods, therapeutic agents and uses thereof |
| US10732173B2 (en) | 2015-09-15 | 2020-08-04 | The Trustees Of Columbia University In The City Of New York | Use of aldehyde dehydrogenase as biomarker for beta-cell dysfunction and loss |
| CN106979982B (zh) * | 2016-01-19 | 2021-01-05 | 上海市第六人民医院 | 一种用于糖尿病风险预测、治疗评价的方法及试剂盒 |
| JP6757870B1 (ja) * | 2018-12-27 | 2020-09-23 | 公立大学法人奈良県立医科大学 | 間質性膀胱炎の診断方法 |
| IL321485A (en) * | 2022-12-14 | 2025-08-01 | Luminous Mind Inc | Treatment of psychological symptoms affecting other medical conditions (PFAOMC) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2764989B1 (fr) * | 1997-06-20 | 1999-08-27 | Pasteur Sanofi Diagnostics | Procede de dosage du c-peptide |
| US7700555B2 (en) * | 2004-07-15 | 2010-04-20 | Joslin Diabetes Center, Inc. | Methods of treating diabetes |
| JP4522222B2 (ja) * | 2004-10-22 | 2010-08-11 | 扶桑薬品工業株式会社 | 血中脂肪酸濃度測定による心疾患の早期診断方法 |
| EP2126589A4 (en) * | 2007-02-22 | 2011-06-08 | Lipomics Technologies Inc | METABOLISM AND DIABETIC SUFFERING AND METHOD OF USE THEREOF |
| BRPI0815095B1 (pt) * | 2007-07-17 | 2021-04-13 | Metabolon, Inc | Método de classificação de um indivíduo de acordo com a tolerância à glicose predita em tolerância à glicose normal (ngt), tolerância à glicose de jejum prejudicada (ifg), ou tolerância à glicose prejudicada (igt), para diabetes tipo 2, método de determinação da suscetibilidade de um indivíduo a diabetes tipo 2 e método de monitoramento da progressão ou regressão do pré- diabetes em um indivíduo |
| WO2010005982A2 (en) * | 2008-07-07 | 2010-01-14 | The General Hospital Corporation | Multiplexed biomarkers of insulin resistance |
| WO2010114897A1 (en) * | 2009-03-31 | 2010-10-07 | Metabolon, Inc. | Biomarkers related to insulin resistance and methods using the same |
-
2012
- 2012-09-11 JP JP2014530734A patent/JP6158186B2/ja active Active
- 2012-09-11 WO PCT/US2012/054640 patent/WO2013039898A1/en not_active Ceased
- 2012-09-11 EP EP12831223.8A patent/EP2756095A4/en not_active Withdrawn
- 2012-09-11 US US14/344,655 patent/US10302663B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014532168A5 (enExample) | ||
| JP2012522989A5 (enExample) | ||
| JP2015064362A5 (enExample) | ||
| MX2018012580A (es) | Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia. | |
| JP2009538607A5 (enExample) | ||
| ATE440151T1 (de) | Verfahren zur beurteilung eines krankheitzustandes mittels nachweis von partikel- und nicht partikelgebundenen nukleinsäuren in blutplasma und -serum | |
| EA201170332A1 (ru) | Способ идентификации факторов риска заболеваний | |
| BR112016004320A2 (pt) | biossensor, sistema, kit, métodos de determinação ou de identificação e de quantificação de uma concentração de amônia ou íon amônio, de diagnóstico de uma doença metabólica em um sujeito, de determinação da resposta do paciente a uma terapia, de fabricação de um biossensor, de um sistema ou de qualquer tira de teste e de detecção da presença, ausência, ou quantidade de aminoácidos em uma amostra, e, tira de teste | |
| WO2008091814A3 (en) | Assessment of asthma and allergen-dependent gene expression | |
| PE20141450A1 (es) | Ensayo de lisiloxidasa-homologo 2 y metodos de uso del mismo | |
| WO2020055954A3 (en) | Methods for detecting liver diseases | |
| WO2014179424A3 (en) | Lipidomic biomarkers | |
| BR112019000709A8 (pt) | Sistema para avaliar uma condição tratável com antibióticos em relação a um usuário e método para avaliar uma condição associada a antibióticos em relação a um primeiro usuário | |
| WO2012006056A3 (en) | Ccr6 as a biomarker of alzheimer's disease | |
| JP2016516985A5 (enExample) | ||
| EP2044212A4 (en) | METHOD FOR IDENTIFYING PATIENTS WITH INCREASED RISK FOR AN UNWANTED HEART CIRCUIT EVENT | |
| MX2014011045A (es) | Metodo para seleccionar o identificar un sujeto para la terapia antagonista vib. | |
| WO2008012692A3 (en) | Assay for efficacy of histone deacetylase inhibitors | |
| JP2013526863A5 (enExample) | ||
| BR112014007947A2 (pt) | método para monitoramento, diagnóstico e/ou prognóstico de distúrbios relacionados à hipoxia usando nfat5 | |
| HK1258207A1 (zh) | 基於鉴别和改善肝功能障碍来诊断和治疗帕金森病 | |
| WO2014044700A1 (en) | Determination of tryptophan metabolites for assessing liver cell function | |
| RU2013115041A (ru) | Способ оценки функционального состояния лимфоцита человека | |
| Bhatt et al. | Clinical laboratory experience with noninvasive prenatal testing: update on clinically relevant metrics | |
| JP2014208601A5 (enExample) |